Cohance Lifesciences Limited CC-Sep24.pdf · 2024-11-12
The f irst question I have on the pharma CDMO side within Suven which was registered around Rs. 200 crore revenue with double digit growth. Also, you have mentioned there that it is led by BD efforts and microenvironment. So, if management can elaborate more on this line for the BD efforts and the micro what had changed during the quarter? And also, if you can provide color within CDMO whether it has been led by development revenues or the commercial revenues?
So, Mr. Prasada, for Suven specifically after new management have come in, are we seeing traction, which is now resulting into good growth, is that the right understanding?